11-?Keto-?beta-?boswellic acid-product

Description	11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor; it exerts dose dependent cardioprotective effect manifested by dose-dependent reduction in serum lactate dehydrogenase
In vitro	A total of ten transformed compounds were isolated and purified, and their chemical structures were characterized as 7β-hydroxy-11-keto-β-boswellic acid; 7β, 15α±-dihydroxy-11-keto-β-boswellic acid ; 7β, 16β-dihydroxy-11-keto-β-boswellic acid; 7β, 16α±-dihydroxy-11-keto-β-boswellic acid; 7β, 22β-dihydroxy-11-keto-β-boswellic acid; 7β, 21β-dihydroxy-11-keto-β-boswellic acid; 7β, 20β-dihydroxy-11-keto-β-boswellic acid; 7β, 30-dihydroxy-11-keto-β-boswellic acid; 3α±, 7β-dihydroxy-11-oxours-12-ene-24, 30-dioic acid and 3α±, 7β-dihydroxy-30-(2-hydroxypropanoyloxy)-11-oxours-12-en-24-oic acid by various spectroscopic methods. The biotransformation processes include hydroxylation, oxidation and esterification. Primary structure-activity relationships (SAR) of inhibitory effects on NO production in RAW 264.7 macrophage cells are discussed[1]
Synonyms	11-Keto-beta-boswellic acid, 11-酮基-BETA-乳香酸
molecular weight	470.68
Molecular formula	C30H46O4
CAS	17019-92-0
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year
Solubility	DMSO: 22.5 mg/mL (47.8 mM)
References	1. Biotransformation of 11-keto-β-boswellic acid by Cunninghamella blakesleana.Phytochemistry. 2013 Dec;96:330-6.

PeptideDB